FI972584L - Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi - Google Patents

Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi Download PDF

Info

Publication number: FI972584L
Authority: FI; Finland
Prior art keywords: atherosclerosis; ones; treatment; substituted azetidin; azetidin
Prior art date: 1994-12-22

Application number

FI972584A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI972584A7 (fi

FI972584A0 (fi

Inventor

Deirdre Mary Bernadette Hickey

Colin Andrew Leach

Robert John Ife

David Graham Tew

Dashyant Dhanak

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-22

Filing date

1995-12-20

Publication date

1997-08-19

1994-12-22 Priority claimed from GBGB9426020.5A external-priority patent/GB9426020D0/en

1994-12-23 Priority claimed from GBGB9426030.4A external-priority patent/GB9426030D0/en

1995-06-08 Priority claimed from GBGB9511599.4A external-priority patent/GB9511599D0/en

1995-06-08 Priority claimed from GBGB9511600.0A external-priority patent/GB9511600D0/en

1995-12-20 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

1997-06-17 Publication of FI972584A0 publication Critical patent/FI972584A0/fi

1997-08-19 Publication of FI972584A7 publication Critical patent/FI972584A7/fi

1997-08-19 Publication of FI972584L publication Critical patent/FI972584L/fi

Links

201000001320 Atherosclerosis Diseases 0.000 title 1
MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

FI972584A 1994-12-22 1995-12-20 Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi FI972584L (fi)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB9426020.5A GB9426020D0 (en)	1994-12-22	1994-12-22	Novel compounds
GBGB9426030.4A GB9426030D0 (en)	1994-12-23	1994-12-23	Novel compounds
GBGB9511599.4A GB9511599D0 (en)	1995-06-08	1995-06-08	Novel compounds
GBGB9511600.0A GB9511600D0 (en)	1995-06-08	1995-06-08	Novel compounds
PCT/EP1995/005130 WO1996019451A1 (fr)	1994-12-22	1995-12-20	Azetidin-2-ones substituees, destinees au traitement de l'atherosclerose

Publications (3)

Publication Number	Publication Date
FI972584A0 FI972584A0 (fi)	1997-06-17
FI972584A7 FI972584A7 (fi)	1997-08-19
FI972584L true FI972584L (fi)	1997-08-19

Family

ID=27451242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI972584A FI972584L (fi)	1994-12-22	1995-12-20	Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi

Country Status (24)

Country	Link
US (1)	US5990102A (fr)
EP (1)	EP0799200A1 (fr)
JP (1)	JPH11500415A (fr)
CN (1)	CN1175246A (fr)
AP (1)	AP9701007A0 (fr)
AR (1)	AR002012A1 (fr)
AU (1)	AU704407B2 (fr)
BG (1)	BG101687A (fr)
BR (1)	BR9510420A (fr)
CA (1)	CA2208530A1 (fr)
CZ (1)	CZ192297A3 (fr)
DZ (1)	DZ1958A1 (fr)
FI (1)	FI972584L (fr)
HU (1)	HUT77089A (fr)
IL (1)	IL116485A0 (fr)
MA (1)	MA23834A1 (fr)
MX (1)	MX9704736A (fr)
NO (1)	NO972909L (fr)
NZ (1)	NZ298416A (fr)
OA (1)	OA10737A (fr)
PL (1)	PL320937A1 (fr)
SK (1)	SK80397A3 (fr)
TR (1)	TR199501655A2 (fr)
WO (1)	WO1996019451A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0840725A1 (fr) *	1995-07-01	1998-05-13	Smithkline Beecham Plc	Derives de l'azetidinone pour le traitement de l'atherosclerose
JP2000505063A (ja) *	1995-12-08	2000-04-25	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	アテローム性動脈硬化症の治療のためのアゼチジノン化合物
JP2000502079A (ja) *	1995-12-08	2000-02-22	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
GB9608649D0 (en) *	1996-04-26	1996-07-03	Smithkline Beecham Plc	Novel compounds
HUP9901359A3 (en) *	1996-04-26	2000-03-28	Smithkline Beecham Plc	Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them
EP1099690A4 (fr) *	1998-07-23	2001-10-17	Shionogi & Co	Composes de beta-lactame monocycliques et inhibiteurs de la chymase les renfermant
NZ520752A (en)	2000-02-16	2004-03-26	Smithkline Beecham P	Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
GB0024808D0 (en)	2000-10-10	2000-11-22	Smithkline Beecham Plc	Novel compounds
US6982251B2 (en) *	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
DK1355644T3 (da)	2001-01-26	2006-10-23	Schering Corp	Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
HU230253B1 (hu)	2001-01-26	2015-11-30	Merck Sharp & Dohme Corp	Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja)	2001-09-21	2005-02-10	シェーリング　コーポレイション	ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
WO2004043457A1 (fr)	2002-11-06	2004-05-27	Schering Corporation	Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) *	2003-03-07	2006-08-31	シェーリング　コーポレイション	置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
JP4589919B2 (ja)	2003-03-07	2010-12-01	シェーリングコーポレイション	高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CA2517571C (fr)	2003-03-07	2011-07-05	Schering Corporation	Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
EP1747014A4 (fr) *	2004-05-03	2007-09-12	Ilypsa Inc	Modulation de la lysophosphatidylcholine et traitement des etats induits par un regime alimentaire
EP2977452A3 (fr)	2007-05-11	2016-05-25	Thomas Jefferson University	Procédés de traitement et de prévention de maladies et de troubles neurodégénératifs
CN101687009A (zh)	2007-05-11	2010-03-31	宾夕法尼亚大学理事会	治疗皮肤溃疡的方法
US8962633B2 (en)	2007-05-11	2015-02-24	Thomas Jefferson University	Methods of treatment and prevention of metabolic bone diseases and disorders
KR101861883B1 (ko)	2010-12-06	2018-05-28	글락소 그룹 리미티드	Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
ES2847883T3 (es)	2010-12-17	2021-08-04	Glaxo Group Ltd	Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
EP2725024A4 (fr)	2011-06-27	2014-12-03	Shanghai Inst Materia Medica	Composé hétérocyclique azole, procédé de préparation, composition pharmaceutique et utilisation
EP2736908A1 (fr)	2011-07-27	2014-06-04	Glaxo Group Limited	Composés pyrimidones bicycliques
EP2739627A4 (fr)	2011-07-27	2015-01-21	Glaxo Group Ltd	Composés 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one et utilisation en tant qu'inhibiteurs de lp-pla2
CA2899124A1 (fr)	2013-01-25	2014-07-31	Glaxosmithkline Intellectual Property Development Limited	Composes
BR112015017397A2 (pt)	2013-01-25	2017-07-11	Glaxosmithkline Ip Dev Ltd	compostos pirimidona bicíclica como inibidores de lp-pla2
UY35276A (es)	2013-01-25	2014-08-29	Glaxosmithkline Ip Dev Ltd	Nuevos compuestos que inhiben la actividad de Lp-PLA2
WO2015179293A1 (fr) *	2014-05-18	2015-11-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Activateurs et inhibiteurs de petites molécules de lécithine-cholestérol acyltransférase
WO2016012916A1 (fr)	2014-07-22	2016-01-28	Glaxosmithkline Intellectual Property Development Limited	Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016012917A1 (fr)	2014-07-22	2016-01-28	Glaxosmithkline Intellectual Property Development Limited	Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
CN114805389B (zh)	2019-11-09	2023-08-29	上海赛默罗生物科技有限公司	三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh)	2021-05-07	2022-11-08	上海赛默罗生物科技有限公司	嘧啶酮衍生物、其制备方法、药物组合物和用途
TWI896037B (zh)	2023-07-17	2025-09-01	大陸商上海樞境生物科技有限公司	雙環[5,6]咪唑嘧啶酮類衍生物、其製備方法和應用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0010358A1 (fr) *	1978-09-20	1980-04-30	Glaxo Group Limited	Composés de bêta-lactame, procédés pour leur préparation, compositions les contenant, intermédiaires utilisables dans leur préparation et méthodes pour leur production
US4680391A (en) *	1983-12-01	1987-07-14	Merck & Co., Inc.	Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL99658A0 (en) *	1990-10-15	1992-08-18	Merck & Co Inc	Substituted azetidinones and pharmaceutical compositions containing them

1995
- 1995-12-20 AR ARP950100660A patent/AR002012A1/es unknown
- 1995-12-20 AP APAP/P/1997/001007A patent/AP9701007A0/en unknown
- 1995-12-20 NZ NZ298416A patent/NZ298416A/xx unknown
- 1995-12-20 JP JP8519527A patent/JPH11500415A/ja active Pending
- 1995-12-20 CN CN95197606A patent/CN1175246A/zh active Pending
- 1995-12-20 AU AU43898/96A patent/AU704407B2/en not_active Ceased
- 1995-12-20 SK SK803-97A patent/SK80397A3/sk unknown
- 1995-12-20 FI FI972584A patent/FI972584L/fi unknown
- 1995-12-20 PL PL95320937A patent/PL320937A1/xx unknown
- 1995-12-20 CZ CZ971922A patent/CZ192297A3/cs unknown
- 1995-12-20 BR BR9510420-8A patent/BR9510420A/pt unknown
- 1995-12-20 EP EP95942734A patent/EP0799200A1/fr not_active Withdrawn
- 1995-12-20 US US08/860,162 patent/US5990102A/en not_active Expired - Fee Related
- 1995-12-20 CA CA002208530A patent/CA2208530A1/fr not_active Abandoned
- 1995-12-20 DZ DZ950141A patent/DZ1958A1/fr active
- 1995-12-20 MA MA24105A patent/MA23834A1/fr unknown
- 1995-12-20 HU HU9701948A patent/HUT77089A/hu unknown
- 1995-12-20 WO PCT/EP1995/005130 patent/WO1996019451A1/fr not_active Ceased
- 1995-12-20 MX MX9704736A patent/MX9704736A/es unknown
- 1995-12-21 IL IL11648595A patent/IL116485A0/xx unknown
- 1995-12-22 TR TR95/01655A patent/TR199501655A2/xx unknown
1997
- 1997-06-20 OA OA70034A patent/OA10737A/en unknown
- 1997-06-20 NO NO972909A patent/NO972909L/no unknown
- 1997-06-26 BG BG101687A patent/BG101687A/xx unknown

Also Published As

Publication number	Publication date
IL116485A0 (en)	1996-08-04
OA10737A (en)	2002-12-10
CN1175246A (zh)	1998-03-04
AP9701007A0 (en)	1997-07-31
AU704407B2 (en)	1999-04-22
NO972909L (no)	1997-08-20
FI972584A7 (fi)	1997-08-19
PL320937A1 (en)	1997-11-10
EP0799200A1 (fr)	1997-10-08
FI972584A0 (fi)	1997-06-17
BR9510420A (pt)	2004-04-20
NZ298416A (en)	1999-03-29
AU4389896A (en)	1996-07-10
CZ192297A3 (en)	1997-11-12
HUT77089A (hu)	1998-03-02
AR002012A1 (es)	1998-01-07
MA23834A1 (fr)	1996-10-01
BG101687A (bg)	1998-02-27
JPH11500415A (ja)	1999-01-12
SK80397A3 (en)	1998-01-14
DZ1958A1 (fr)	2002-02-17
US5990102A (en)	1999-11-23
WO1996019451A1 (fr)	1996-06-27
TR199501655A2 (tr)	1996-07-21
CA2208530A1 (fr)	1996-06-27
NO972909D0 (no)	1997-06-20
MX9704736A (es)	1997-10-31

Publication	Publication Date	Title
FI972584A0 (fi)	1997-06-17	Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi
ZA959100B (en)	1996-06-20	Azetidinone derivatives for the treatment of atherosclerosis
BR9709196A (pt)	1999-05-25	Derivados de azetidinona para o tratamento de aterosclerose
FI954880L (fi)	1996-04-15	Käsiteltyjä epäorgaanisia kiintoaineita
DK0777671T3 (da)	2000-07-24	Spiro-azabicykliske forbindelser
DE69520558D1 (de)	2001-05-10	Halogenierungsverfahren
NO976158D0 (no)	1997-12-30	Azetidinon-derivater for behandling av atherosklerose
ID17723A (id)	1998-01-22	Senyawa untuk pengobatan
DE69520998D1 (de)	2001-06-28	Faserbehandlungszusammensetzungen
IS4789A (is)	1998-06-30	Meðferðarefnasambönd
DE69507032D1 (de)	1999-02-11	Chlorhydrin-verfahren
FI970151A0 (fi)	1997-01-14	Viruksenvastaisesti vaikuttavia difluoristatoniyhdisteitä
BR9509740A (pt)	1997-10-21	Compostos 18-nor-vitamina d
FI971971A7 (fi)	1997-05-12	Pyridatsinokinoliiniyhdisteitä
DE69417067D1 (de)	1999-04-15	Verbundstoffe
NO962812D0 (no)	1996-07-03	Fremgangsmåte for behandling av nervebetennelse
KR960022630U (ko)	1996-07-20	용광로의 풍구
FI973780A0 (fi)	1997-09-25	Arrangemang foer bestaemning av laekemedelsdosering
UA25833C2 (uk)	1999-02-26	Засіб для лікуваhhя мелаhомобластом
FI942481A0 (fi)	1994-05-27	Foerfarande foer minskning av vibration i spelklubbor
FI943432A0 (fi)	1994-07-20	Tillverkning av plastroerelement foersett med loesmuffoerbandsmedel
FI943862A0 (fi)	1994-08-22	Foerfarande foer framstaellning av en kretsmoensterfolie
FI944868A0 (fi)	1994-10-17	Foerfarande foer foerbaettring av en braennare
FI940614A0 (fi)	1994-02-10	Foerfarande foer framstaellning av jordfoerbaettringsaemnet
FI1727U1 (fi)	1995-01-26	Ansiktsskydd i samband med haortvaettning